Shire’s ViroPharma Purchase Aims To Build Rare Disease Giant
Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.
You may also be interested in...
CHMP Clears Pierre Fabre’s Hemangiol For Children, Under Rarely Used Pediatric Pathway
Europe’s top scientific advisory panel also gave positive recommendations to BioMarin’s orphan drug Vimizim for use in mucopolysaccharidosis type IVA, and the compassionate use of a fixed combination of two of Gilead Science’s antivirals in hepatitis C, sofosbuvir and ledipasvir, after its meeting Feb. 17-20.
Shire Plans New Cinryze Versions, Promises Fresh M&A And Innovation
Shire ended 2013 on a high note with promises to keep up its fast but disciplined pace to generate strong profits and cash for use in fresh drug innovation and further M&A activity.
Biopharma Dealmaking Quarterly Statistics, Q4 2013
Biopharma financing totaled $6.4 billion, a 39% increase over Q3. Twenty-three M&As were completed with a combined potential value of $19.8 billion, and there were 103 biopharma alliances totaling $2.5 billion in potential pre-commercialization value, down 25% from the previous quarter.